169 related articles for article (PubMed ID: 16925731)
1. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Buchacz K; Brooks JT; Tong T; Moorman AC; Baker RK; Holmberg SD; Greenberg A;
HIV Med; 2006 Oct; 7(7):451-6. PubMed ID: 16925731
[TBL] [Abstract][Full Text] [Related]
2. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Izzedine H; Hulot JS; Vittecoq D; Gallant JE; Staszewski S; Launay-Vacher V; Cheng A; Deray G;
Nephrol Dial Transplant; 2005 Apr; 20(4):743-6. PubMed ID: 15741212
[TBL] [Abstract][Full Text] [Related]
3. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
4. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Winston A; Amin J; Mallon P; Marriott D; Carr A; Cooper DA; Emery S
HIV Med; 2006 Mar; 7(2):105-11. PubMed ID: 16420255
[TBL] [Abstract][Full Text] [Related]
5. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
[TBL] [Abstract][Full Text] [Related]
6. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Antoniou T; Raboud J; Chirhin S; Yoong D; Govan V; Gough K; Rachlis A; Loutfy M
HIV Med; 2005 Jul; 6(4):284-90. PubMed ID: 16011534
[TBL] [Abstract][Full Text] [Related]
7. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
[TBL] [Abstract][Full Text] [Related]
8. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV
Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Della Negra M; de Carvalho AP; de Aquino MZ; da Silva MT; Pinto J; White K; Arterburn S; Liu YP; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2012 May; 31(5):469-73. PubMed ID: 22301477
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
[TBL] [Abstract][Full Text] [Related]
11. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Parsonage MJ; Wilkins EG; Snowden N; Issa BG; Savage MW
HIV Med; 2005 Sep; 6(5):341-6. PubMed ID: 16156882
[TBL] [Abstract][Full Text] [Related]
12. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
13. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Soler-Palacín P; Melendo S; Noguera-Julian A; Fortuny C; Navarro ML; Mellado MJ; Garcia L; Uriona S; Martín-Nalda A; Figueras C
AIDS; 2011 Jan; 25(2):171-6. PubMed ID: 21076275
[TBL] [Abstract][Full Text] [Related]
15. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
Tan LK; Gilleece Y; Mandalia S; Murungi A; Grover D; Fisher M; Atkins M; Nelson M
J Viral Hepat; 2009 Jul; 16(7):471-8. PubMed ID: 19457140
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Nurutdinova D; Onen NF; Hayes E; Mondy K; Overton ET
Ann Pharmacother; 2008 Nov; 42(11):1581-5. PubMed ID: 18957630
[TBL] [Abstract][Full Text] [Related]
17. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Woratanarat K; Kanjanabuch T; Suankratay C
J Med Assoc Thai; 2013 Apr; 96(4):432-9. PubMed ID: 23691697
[TBL] [Abstract][Full Text] [Related]
19. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Fux CA; Simcock M; Wolbers M; Bucher HC; Hirschel B; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Elzi L; Furrer H;
Antivir Ther; 2007; 12(8):1165-73. PubMed ID: 18240857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
